HER-2/neu expression in lesions of uterine cervix: is it reliable and consistent?
This study was conducted to evaluate the expression of HER-2/neu oncogene in the lesions of the uterine cervix and to determine its correlation with histological type of malignancy, grade and clinical stage of presentation. One hundred cervical specimens were included in this study. These comprised cases with diagnosis of benign epithelial lesions, squamous cell carcinoma, adenocarcinoma, carcinoma cervix with glandular differentiation and cervical intraepithelial neoplasia. HER-2/neu immunostaining was performed by streptovidin-biotin peroxidase method. Higher expression of HER-2/neu was noted in malignant lesions as compared to benign lesions. Intensity of staining also correlated with clinical stage of presentation, lymph node metastasis and presence of parametrial extension. The over-expression of HER-2 oncoprotein is associated with poor prognosis, metastatic potential and aggressive biological behavior.
Gupta
Nidhi
N
Department of Pathology, Post Graduate Institute of Medical Sciences, Rohtak-124 001, Haryana, India.
Singh
Sunita
S
Marwah
Nisha
N
Kumar
Sanjay
S
Chabra
Sonia
S
Sen
Rajeev
R
D000230:Adenocarcinoma / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000473:pathology; D005260:Female; D017573:Focal Epithelial Hyperplasia / Q000473:pathology; D020869:Gene Expression Profiling; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis* / Q000235:genetics; D012720:Severity of Illness Index; D013223:Statistics as Topic; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis* / Q000473:pathology*; D002578:Uterine Cervical Dysplasia / Q000473:pathology
D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human